1,637 search results for “drug delivery” in the Public website
-
The LeiCNS-PK3.0 model development and applications: healthy-to-diseased CNS pharmacokinetic translation
Accurate prediction of the unbound drug concentration-time profile at the CNS target site is crucial for the assessment of the right drug concentration-effect relationship. PBPK models have supported the PK prediction of the CNS target sites and the translation of PK data between species and between…
-
Smartmix: A new generation of efficient biomedical research
Can we find and commercialise new treatments for chronic disease that affect our ageing population? And how can we customise this research and development programme to the small but highly-developed Netherlands research economy?
-
Modeling interactions to unravel biomarkers for disease progression and treatment response
The aim of this project is to explore the use of statistical interaction models to quantify cross-omics and omics-drug interactions in large-scale clinical and experimental datasets
-
About the programme
Drug Discovery and Safety consists of 120 European Credit Transfer System (EC) points.
-
Art of Captivity / Arte del Cautiverio
Art of Captivity / Arte del Cautiverio tells a compelling story about Central America's drug war through a series of rich photographs. The book, which is entirely bilingual in English and Spanish, focuses on Guatemala, which has become the primary point of transit for cocaine produced in the Andes and…
-
European Lead Factory
The European Lead Factory has been created with the ultimate goal to develop lead drug candidates to address neglected diseases including bacterial infections, psychiatric disorders and oncology.
-
Student projects
Are you looking for a research project?
-
Phenotypic screening with 3D cell-based assays
Traditional drug discovery approaches have been hampered by (in vitro) cell-culture models that poorly represent the situation in the human body.
-
Strategy
The Division of Systems Pharmacology and Pharmacy (SPP) aims to develop precision medicine approaches to characterize and predict variation in treatment response and enhance translational drug development strategies.
-
Targeting the adenosinergic system
Adenosine is an endogenous ligand which exerts its action by activating adenosine receptors (ARs), while its circulating levels are controlled via a variety of mechanism and proteins, amongst others the equilibrative nucleoside transporters (ENTs).
-
Career prospects
After graduation you have a lot of opportunities: academics are highly sought after in Dutch secondary education or mbo teaching. You can also aim for a management position or work as a researcher within the field of Life Sciences.
-
Chemical Probe Facility
The Chemical Probe Facility is part of the Leiden Early Drug Discovery & Development (LED3) center. Activity-based protein profiling (ABPP) is one of the pillars of chemical biology. ABPP determines the activity of entire protein families in living cells and tissues under physiological conditions, such…
-
Prediction of human (CNS) target site concentrations in health and disease
Prediction of human (CNS) target site concentrations in health and disease In the vision of Prof. de Lange we will only be able to predict human (central nervous system, CNS) target site concentrations and effects if we perform systematic, condition-dependent, integrative, and strictly quantitative…
-
Mathematical modelling of adverse outcome pathways
In this project, we aim to develop mathematical models to mechanistically and quantitatively predict the dynamics of cellular stress pathway activation and its relation with toxic effects when cells are exposed to various toxicants.
-
Biological evaluations of nanocarriers to improve the effectiveness of colorectal cancer treatment
PhD defence
-
More effective blocking of CCR2 receptor
The discovery of new medicines is a tedious and lengthy process. On average, over 10,000 molecules need to be studied for one to become a drug and reach the patient. Part of that process are the very costly clinical trials in humans, and candidate drugs often fail due to side effects or lack of efficacy.…
-
Novel Chemical Modalities
The Novel chemical modalities research group is headed by Assistant Professor Sebastian Pomplun. Sebastian started at the division of Medicinal Chemistry within the LACDR in September 2021. His lab develops technologies for the discovery of novel chemical modalities that can address challenging drug…
-
Phenomix Field Lab offers promising healthcare solutions
In the Phenomix Medical Delta Field Lab, which was officially opened on Thursday 9 July, scientists, healthcare institutions and businesses work together to develop innovative applications in the field of metabolomics. This research field makes it possible to determine which drugs will be effective…
-
Illuminating N-acylethanolamine biosynthesis with new chemical tools
In this thesis, the discovery and optimization is described of chemical tools to study the N-acylethanolamine (NAE) biosynthetic pathway.
-
In vivo modelling of Ewing sarcoma in zebrafish
Promotores: Prof.dr. P.C.W. Hogendoorn & Prof.dr. H.P. Spaink, Co-promotor: Dr. B.E. Snaar-Jagalska
-
Cancer chess: molecular insights into PARP inhibitor resistance
The clinical potential of applying synthetic lethality to cancer treatment is famously demonstrated by the BRCA1/PARP1 paradigm: a tumor specific defect in BRCA1 – a component of the DNA double-strand break (DSB) repair pathway homologous recombination (HR) – results in a remarkable sensitivity to PARP1…
-
Research
The current projects of the Molecular Physiology group focus on proteins of the endocannabinoid system, kinases and antibacterial targets. MSc- and BSc-students can contact Jessica van Krimpen-Kraaijenoord to apply for research internships.
-
A much-needed new class of antibiotics
Antimicrobial resistance (AMR) is the phenomenon that pathogens become insensitive to the antibiotics that we use against them. A growing number of pathogens is becoming resistant, with methicillin-resistant S. aureus (MRSA) as the most famous example. But while the threat of AMR represents a slow-moving…
-
Single cell technologies for mechanobiology and mechanopharmacology
Mechanobiology is a major area in biology, however, mechanics is currently a missing element in drug development pipelines. This has led to a high cost for the society. Mechanotoxicity of drugs often appears as a long-term side effect of drugs, and has led to removal of drugs from the market. Furthermore,…
-
Concepts and applications for evidence-based dosing in morbidly obese patients before and after weight loss surgery
Promotor: C.A.J. Knibbe, Co-promotores: H.P.A. van Dongen, B. van Ramshorst
-
Prediction of brain target site concentrations on the basis of CSF PK: impact of mechanisms of blood-to-brain transport and within brain distribution
Promotor: Prof.dr. M. Danhof, Co-promotor: E.C.M. de Lange
-
Systems pharmacology of human neuroendocrine disease entities
An important hormone excreting gland in the human body is the pituitary
-
Laura Heitman appointed as Professor of Molecular Pharmacology
As of 1 November, Laura Heitman has been appointed full Professor of Molecular Pharmacology at the Leiden Academic Centre for Drug Research (LACDR). Heitman has been working on the understanding and improvement of drug-receptor interactions in early drug discovery. ‘My ultimate aim is to make medicines…
-
Oncode Accelerator
Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process. Leiden University, the LUMC and other partners will implement this new way…
-
Hit Discovery
The goal of hit discovery is to identify suitable chemical starting points to modulate a drug target. A hit can be, a.o., a small molecule, a protein or mRNA. Hit identification is performed via rational design, genome mining, (targeted) library screening, or in silico approaches.
-
Contact
Division contact information & address
-
New techniques for tuberculosis treatment
About nine million people worldwide contract tuberculosis each year. Research into new treatment for this disease has received fresh stimulus with more efficient techniques and a new understanding of how the tuberculosis bacteria works.
-
Systems Biomedicine and Pharmacology (MSc)
The two-years master’s specialisation System Biomedicine and Pharmacology at Leiden university focuses on predicting drug response with computational modelling, developing individualised therapies, and developing innovative analytical tools for personalised health strategies.
-
Allosteric modulation and ligand binding kinetics at the Kv11.1 channel
Promotor: Prof.dr. A.P. IJzerman, Co-Promotor: L.H. Heitman
-
The activation mechanisms of G protein-coupled receptors: the case of the adenosine A2B and HCA2/3 receptors
Promotor: A.P. IJzerman
-
Dosing considerations for preterm neonates: from pharmacometrics to clinical practice
Prematurely born neonates require, amongst others, pharmaceutical therapy. Dosing guidelines for these therapies are often based on data from term born neonates or older infants, while these are not necessarily similar to prematurely born neonates.
-
How Oncode-PACT is bringing new cancer medicines closer with 325 million in Growth Fund money
How can you ensure that more experimental drugs reach the finish line? At the moment, only one in twenty cancer drugs that are tested on humans makes it to the market. This is an enormous loss for patients and society. With a grant from the National Growth Fund, Oncode-PACT aims to efficiently select…
-
Laura Heitman uses her expertise to fight cancer
Seven talented female scientists join the fight against cancer of the Oncode Insitute. Laura Heitman of the Leiden Academic Centre for Drug Research is one of the new Junior Investigators. ‘I hope to discover new druggable targets’.
-
New resource for the modelling community
The Repository from the Drug Disease Model Resources (DDMoRe) consortium provides a home to a collection of computational models of disease and drug action that have been used in pharmaceutical and/or academic research. This publically available open-access resource will make it easier for researchers…
- Research
-
Quantitative Clinical Pharmacology
The Quantitative Clinical Pharmacology group is led by Prof. Dr. Catherijne Knibbe. Her research group aims to define how to adjust a drug dose in special patient populations such as (prematurely born) neonates or children, obese individuals or critically ill patients. Through combining the statistical…
-
25 Years Bio-Pharmaceutical Sciences: Combined fascination
25 Years ago, the Center for Bio-Pharmaceutical Sciences was founded at Leiden University; one year later, in 1985, the education program of Bio-Pharmaceutical Sciences started. On Friday September 18th, this was celebrated with a Symposium, an anniversary booklet, and a grand party.
-
Laura Heitman nominated for Prix Galien
Laura Heitman of the Leiden Academic Center for Drug Research (LACDR) has been nominated for the Prix Galien Research Award. This important pharmaceutical prize honors young, prominent researchers whose scientific research is of great importance for fundamental or clinical drug research.
-
Precision modeling of breast cancer in the CRISPR era
The molecular mechanisms that instigate a healthy cell to become malignant are fueled by (epi)genetic alterations in so-called driver genes.
-
Education
Our educational programmes span the entire spectrum of pharmaceutical education, from training of the next generation drug researchers in the areas of drug design, drug action, and drug use to educating the pharmacists of the future.
-
Research
Tuberculosis causes 1.5 million deaths yearly and anti-tuberculosis therapies are threatened by emergence of drug resistance. Development of innovative drug combinations should be accelerated with the use of translational pharmacological models. Moreover, host-directed therapies (HDT), which stimulate…
-
History
Life Sciences Artificial Intelligence Data Science
-
NMR studies of protein-small molecule and protein-peptide interactions
Promotor: M. Ubbink, Co-promotor: G. Siegal
-
Determining the kinetic profile of ENT1 inhibitors
Supervisor: Anna Vlachodimou
-
Flagships
In CCLS several subgroups have formed, below you can find an overview of these groups with the names of the leading researchers and a short outline of the project.